DOI: http://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20190254

HPV infection: in need of timely intervention

Ankit Chaudhary, Vijay K. Barwal, Shaina Chamotra, Anjali Mahajan

Abstract


Persistent infection with human papilloma virus (HPV) has been proved beyond doubt to be associated with the development of cervical cancer. One woman dies of cervical cancer every 8 minutes in India. As per estimations for the year 2018, about 96922 new cervical cancer cases are diagnosed annually in India and it ranks as the second most common female cancer in all age groups. But being an infectious cause it is possible to contain its development and transmission. Coupled with this, we have a potent vaccine to fight this infection. A well documented account of positive impact of HPV vaccination has been published in numerous studies around the globe. By 2013, its vaccination had been introduced in about fifty countries around the globe. In India also, recently, two HPV vaccination projects for operational feasibility were launched in Andhra Pradesh and Gujarat. In November 2016, Punjab became the first state in the country to include the vaccine in its universal immunization program. This era belongs to women empowerment and we cannot deny them the opportunity of good health. Hence it’s high time India introduces an effective HPV vaccination program.


Keywords


HPV infection, Cervical cancer, HPV vaccine

Full Text:

PDF

References


Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265:472-7.

Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in India. Summary Report 27 July 2017. Available at: http://www.hpvcentre.net/statistics/ reports/IND.pdf. Accessed on 03 December 2018.

Brown DR, Shew ML, Qadari B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital papiloma virus infection in a cohort of closely followed adolescent women. J Infect Dis. 2006;191:182–92.

Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37(6):3–9.

International agency for research on cancer. World Health Organization. Cancer today. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-Uteri-fact-sheet.pdf. Accessed on 12 November 2018.

India against cancer. National Institute of cancer Prevention and research (NICPR). Globocan 2018: India Factsheet. Available at: http://cancerindia.org. in/globocan-2018-india-factsheet/. Accessed on 22 November 2018.

Himachal Pradesh: Regional Cancer Centre; 1998-2008: 116-418.

What Are the Risk Factors for Cervical Cancer? Available at: http://www.cancer.org/cancer /cervicalcancer/detailedguide/cervical-cancer-risk-factors. Accessed on 12 November 2018.

Merck Reports Double-Digit Earnings-Per-Share Growth for Second Quarter 2007.

“October 16, 2009 Approval Letter—Cervarix". U.S. Food and Drug Administration (FDA). 2009. Accessed on 10 November 2018.

"FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV"(press release). 10 December 2014. Accessed on 11 October 2018.

Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36(1):17-23.

Countries using HPV vaccination in national immunization schedule and planned introductions 2013. Available at: http://www.who.int/ immunization/diseases/hpv/decision_implementation/en/. Accessed on 04 November 2018.

Tabrizi, S, Brotherton J, Kaldor J, Skinner S, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis; 2012;206:1645–51.

Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV After Introduction of the Vaccination Program in the United States Pediatrics. 2016;137(3).

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med. 2007;356(19):1928–43.

Judges demand answers after children die in controversial cancer vaccine trial in India 2015 Available at: http://www.dailymail.co.uk/news/ article-2908963/Judges-demand-answers-children-die-controversial-cancer-vaccine-trial-India.html. Accessed on 02 November 2018.

Your daughter needs to be vaccinated for cervical cancer. Here is why 2016. Available at: http://www.hindustantimes.com/india/is-hpv-vaccine-safe-for-my-daughter-yes/story-4gBa5z5rDtxREhNJ6lzzQP.html. Accessed on 05 November 2018.

Punjab launches HPV vaccine with WHO support 2016. Available at: http://www.searo.who.int/ india/mediacentre/events/2016/Punjab_HPV_vaccine/en/. Accessed on 08 October 2018.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–86.